



ALASKA STATE LEGISLATURE

Representative Genevieve Mina

Chair, House Health and Social Services Committee

Serving House District 19: Airport Heights, Mountain View, & Russian Jack

House Bill 195 Explanation of Changes Version A to I (34-LS0909\I) 02.25.26

"An Act relating to the prescription and administration of drugs and devices by pharmacists; relating to reciprocity for pharmacists; and providing for an effective date."

Section 1 adds a new section to AS 08.02 that prohibits the Department of Commerce, Community, and Economic Development from requiring fees for collaborative practice agreements, requiring board approval for collaborative practice agreements, or from defining the nature and scope of services provided under these agreements and requires that each collaborative practice agreement must define the specific patient care services the pharmacist is permitted to provide under that agreement.

Section 5 is amended to adjust the timeframe to complete continuing education (CE) requirements for pain management and opioid use and addiction to align with other types of CE timeframes.

Section 7 is amended to specify that a pharmacist may provide patient care services for a condition requiring a new diagnosis only if they use a test to guide their clinical decision-making and the test is waived under the Clinical Laboratory Improvement Amendments (CLIA).

Section 8 is amended to explicitly exclude the prescription or administration of Schedule IA or IIA state-controlled substances (and Schedule II federal substances) from these services, unless used for treating opioid use disorder in a clinic (medication assisted treatment).

Section 13 updates the effective date from January 1, 2026 to January 1, 2027.